A role for leukotrienes in cyclosporine nephrotoxicity

Kidney International

Volumn 57, Issue 6, 2000, Pages 2586-2593

  Butterly, David W ^b   Spurney, Robert F ^b   Ruiz, Phillip ^b   Griffiths, Robert ^b   Albrightson, Christine ^b   Coffman, Thomas M ^a  

^a DURHAM VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

5 lipoxygenase pathway; Arachidonic acid; Kidney toxicity; Peptidoleukotriene receptor blockade; Tubular vacuolization

Indexed keywords

3 [(2 CARBOXYETHYL)THIO] 3 [2 (8 PHENYLOCTYL)PHENYL]PROPIONIC ACID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

EID: 0008785118     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00118.x     Document Type: Article

References (39)

1. 1. CANADIAN MULTICENTRE TRANSPLANT STUDY GROUP: A randomised clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809-815, 1983
2. 2. CANADIAN MULTICENTRE TRANSPLANT STUDY GROUP: A randomized clinical trial of cyclosporine in cadaveric renal transplantation: Analysis at three years. N Engl J Med 314:1219-1225, 1986
3. 3. KAHAN B: Cyclosporine. N Engl J Med 321:1725-1738, 1989
4. 4. FUETREN G, MIHATSCH M: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326:1654-1660, 1992
5. 5. LICHTIGER S, PRESENT D, KORNBLUTH A, GELERNT I, BAUER J, GALLER G, MICHELASSI F, HANAEUR S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841-1845, 1994
6. 6. MYERS B, ROSS J, NEWTON L, LEUTSCHER J, PERLOTH M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311: 699-705, 1984
7. 7. MYERS B: Cyclosporine nephrotoxicity. Kidney Int 30:964-974, 1986
8. 8. DE MATTOS A, ANDOH T, BENNETT W: Cyclosporine nephropathy: Clinical, histological, and functional aspects. Transplant Rev 10: 225-235, 1996
9. 9. BENNETT W, DE MATTOS A, MEYER M, ANDOH T, BARRY J: Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 50:1089-1100, 1996
10. 10. MIHATSCH M, RYFFLI B, GUDAT F: The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 48:S63-S69, 1995
11. 11. SHIHAB F: Cyclosporine nephropathy: Pathophysiology and clinical impact. Semin Nephrol 16:536-547, 1996
12. 2 receptor antagonists on cyclosporin A renal vasoconstriction. Am J Physiol 267:F443-F449, 1994
13. 13. BURDMANN E, ANDOH T, NAST C, EVAN A, CONNORS B, COFFMAN T, LINDSLEY J, BENNETT W: Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 269:F491-F499, 1995
14. 14. FOGO A, HELLINGS S, INAGAMI T, KON V: Endothelin receptor antagonism is protective in in-vivo acute cyclosporine toxicity. Kidney Int 42:770-774, 1992
15. 15. PERICO N, DADAN J, REMUZZI G: Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1:76-83, 1990
16. 16. PENNER S, JEFFERY J, SMYTH D: Cyclosporine-induced nephrotoxicity in the rat: The effects of alpha 1-adrenoreceptor blockade with prazosin. Transplantation 56:1569-1572, 1993
17. 17. LYSON T, ERMEI L, BELSHAW P, ALBERG D, SCHRFIBER S, VISTOR R: Cyclosporine-and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T cell signaling. Circ Res 73:1101-1109, 1993
18. 18. SHIHAB F, BENNETT W, TANNER A, ANDOH T: Angiotensin II blockade decreases TGF-betal and matrix proteins in Cyclosporine nephropathy. Kidney Int 52:660-673, 1997
19. 19. TUFRO-MCREDDIE A, GOMEZ R, NORLING L, OMAR A, MOORE L, KASKEL F: Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney. Kidney Int 43:615-622, 1993
20. 20. PERICO N, BENIGNI A, ZOJA C, DELAINI F, REMUZZI G: Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporine A. Am J Physiol 251:F581-F587, 1986
21. 4 in mediating cyclosporine-induced acute renal failure. Transplantation 52:873-878, 1991
22. 22. PERICO N, ROSSINI M, IMBERTI O, MALANCHINI B, PLATA C, GASPARI F, BERTANI T, REMUZZI G: Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. J Am Soc Nephrol 2:1398-1404, 1992
23. 23. SPURNEY R, MAVROS S, COLLINS D, RUIZ P, KLOTMAN P, COFFMAN T: Thromboxane receptor blockade improves cyclosporine nephroloxicity in rats. Prostaglandins 39:135-146, 1990
24. 24. COFFMAN T, CARR D, YARGER W, KLOTMAN P: Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 43:283-285, 1987
25. 25. ROGERS T, ELZINGA L, BENNETT W, KELLEY V: Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine-induced nephrotoxicity: Dietary protection by fish oil. Transplantation 45:153-156, 1988
26. 4 on glomerular dynamics in the rat. Am J Physiol 253:F239-F243, 1987
27. 27. LEWIS R, AUSTEN K, SOBERMAN R: Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation to pathobiology in human diseases. (review) N Engl J Med 323:645-654, 1990
28. 4 and peptidoleukotrienes in the pathogenesis of allograft injury. J Immunol 152:867-876, 1994
29. 29. SPURNEY R, RUIZ P, PISETSKY D, COFFMAN T: Enhanced renal leukotriene production in murine lupus: Role of lipoxygenase metabolites. Kidney Int 39:95-102, 1991
30. 30. BUTTERLY D, SPURNEY R, RUIZ, R, PIROTSKY E, BRAQUET P, COFFMAN T: The role of platelet activating factor in kidney transplant rejection in the rat. Kidney Int 48:337-343, 1995
31. 31. THOMSON A, WHITING P, SIMPSON J: Cyclosporine: Immunology, toxicity, and pharmacology in experimental animals. Agents Actions 15:306-327, 1984
32. 32. DE NICOLA L, THOMSON S, WEAD L, BROWN M, GABBAI F: Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 92:1859-1865, 1993
33. 33. BOBADILLA N, TAPIA E, FRANCO M, LOPEZ P, MENDOZA S, GARCIA-TORRES R, ALVARADO J, HERRERA-ACOSTA J: Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 46:773-779, 1994
34. 34. SMITH S, CREECH E, SCHAFFER V, MARTIN L, RAKHIT A, DOUGLAS F, KLOTMAN P, COFFMAN T: The effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity. Kidney Int 41:199-205, 1992
35. 35. BADR K: Arachidonic acid metabolites in glomerular immune injury. Semin Nephrol 11:332-339, 1991
36. 36. BAUD L, PEREZ J, DENIS M, ARDAILLOU R: Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: Effect of indomethacin. J Immunol 138:1190-1195, 1987
37. 4 to rat lung fibroblasts and stimulation of collagen synthesis. Biochemistry 27:2853-2866, 1988
38. 2 in cyclosporine A nephrotoxicity. Kidney Int 34:164-174, 1988
39. 39. YOUNG B, BURDMANN E, JOHNSON R, ALPERS C, GIACHELLI C, ENG E, ANDOH T, BENNETT W, COUSER W, LINDSLEY J, DUYN J: Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 48:439-448, 1995